Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:UMRX

Cogent Biosciences (UMRX) Stock Price, News & Analysis

Cogent Biosciences logo

About Cogent Biosciences Stock (NASDAQ:UMRX)

Advanced Chart

Key Stats

Today's Range
$7.27
$7.73
50-Day Range
$2.35
$13.01
52-Week Range
$0.29
$3.72
Volume
1.86 million shs
Average Volume
1.22 million shs
Market Capitalization
$321.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive UMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter.

UMRX Stock News Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
Cogent Biosciences (COGT) Initiated with a Buy at Scotiabank
See More Headlines

UMRX Stock Analysis - Frequently Asked Questions

Cogent Biosciences, Inc. (NASDAQ:UMRX) announced its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.03. The business earned $0.53 million during the quarter. Cogent Biosciences had a negative trailing twelve-month return on equity of 87.78% and a negative net margin of 96.84%.

Cogent Biosciences (UMRX) raised $75 million in an IPO on Thursday, March 29th 2018. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Morgan Stanley and Cowen acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cogent Biosciences investors own include Advanced Micro Devices (AMD), Tesla (TSLA), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/11/2020
Today
7/06/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:UMRX
Fax
N/A
Employees
72
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$31.83 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$22.50 million
Price / Cash Flow
N/A
Book Value
$1.04 per share
Price / Book
7.29

Miscellaneous

Free Float
N/A
Market Cap
$321.92 million
Optionable
Not Optionable
Beta
3.93
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:UMRX) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners